Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FYN | P06241 | 9/20 | 0.46 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.40 |
| ▸ | IRAK4 | Q9NWZ3 | 3/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | PIM1 | P11309 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.39 |
| ▸ | TNF | P01375 | 2/20 | 0.39 |
| ▸ | CDK9 | P50750 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL625243 | 0.88 | FYN (0.60) | FYNCDK9 | |
| SCHEMBL623828 | 0.88 | FYN (0.46) | FYNPIM1CDK9 | |
| SCHEMBL625495 | 0.86 | PIM1 (0.46) | FYNPIM1 | |
| SCHEMBL624037 | 0.85 | CYP2D6 (0.39) | IRAK4CYP2D6HSD17B10GPR119 | |
| SCHEMBL624978 | 0.82 | FYN (0.51) | FYNHSD17B10PIM1 | |
| SCHEMBL626982 | 0.81 | FYN (0.56) | FYNEGLN2PIM1GPR119 | |
| SCHEMBL625491 | 0.80 | NAMPT (0.41) | GPR119CDK9 | |
| SCHEMBL625407 | 0.79 | PIK3CA (0.45) | FYNCDK9 | |
| SCHEMBL624945 | 0.77 | FYN (0.49) | FYNPIM1 | |
| SCHEMBL623872 | 0.76 | FYN (0.52) | FYNPIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012020217-A1 | AMINO- IMIDAZOLOTHIADIAZOLES FOR USE AS PROTEIN OR LIPID KINASE INHIBITORS | CENTRO NACIONAL DE INVESTIGACIONES ONCOLÓGICAS (CNIO) (ES) | 2012-02-16 | — | — | WO | disclosed |